# Eddingpharm's GB268 Trial Approved in China

> China's NMPA clears Eddingpharm's GB268 Phase 2 colorectal cancer trial.
- Title: Eddingpharm's GB268 Trial Approved in China · BigGo Finance
- Summary: China's NMPA clears Eddingpharm's GB268 Phase 2 colorectal cancer trial. Eddingpharm's GB268 Phase 2 trial for advanced colorectal cancer received China's…
- Keywords: eddingpharm, gb268, nmpa, colorectal cancer, pmmr/mss, phase 2 trial, immunotherapy, finance, markets, Eddingpharm's, Trial, Approved
- Source: BigGo Finance — https://finance.biggo.com/news/1d9e17c9-4a71-4ad4-9cd6-60296cd6f2e2
- Author: BigGo Finance
- Published: 2026-10-12T03:05:55+00:00
- Read time: 1 min
- Topics: eddingpharm, gb268, nmpa, colorectal cancer, pmmr/mss, phase 2 trial, immunotherapy, finance, markets
## NMPA Approval
Eddingpharm's GB268 Phase 2 clinical trial for advanced colorectal cancer received China's National Medical Products Administration approval on October 9.
## Targeted Patient Population
The pMMR/MSS subtype accounts for approximately 95% of advanced colorectal cancer patients and is insensitive to immune monotherapy.
## Clinical Need
Traditional chemotherapy and targeted therapies have reached a plateau in efficacy improvement for this patient group.
## GB268 Mechanism
GB268's fine-tuned modulation of pd-1, ctla-4, and vegf activity improves tumor immune microenvironment and inhibits angiogenesis.
## Phase 1 Data
Preliminary Phase 1 monotherapy data for gb268 is expected to be presented at ESMO in October 2026.
## Breast Cancer Trial
First-patient dosing in a Phase 1b/2 breast cancer trial was completed on August 5, 2026.
## Next Steps
Eddingpharm expects gb268 to advance into phase 2 trials across multiple solid tumor types including breast cancer and colorectal cancer.
## Key takeaway

Eddingpharm's GB268 Phase 2 trial for advanced colorectal cancer received China's NMPA approval on October 9, targeting the pMMR/MSS subtype that makes up 95% of patients.